Title: Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study.
Authors: Fortuny, Joan; Kogevinas, Manolis; Zens, Michael S; Schned, Alan; Andrew, Angeline S; Heaney, John; Kelsey, Karl T; Karagas, Margaret R
Published In BMC Urol, (2007)
Abstract: BACKGROUND: Use of phenacetin and other analgesic and non-steroidal anti-inflammatory drugs (NSAIDs) potentially influences bladder cancer incidence, but epidemiologic evidence is limited. METHODS: We analyzed data from 376 incident bladder cancer cases and 463 controls from a population-based case-control study in New Hampshire on whom regular use of analgesic drugs and NSAIDs was obtained. Odds ratios and 95% confidence intervals were computed using logistic regression with adjustment for potentially confounding factors. Separate models by tumor stage, grade and TP53 status were conducted. RESULTS: We found an elevated odds ratio (OR) associated with reported use of phenacetin-containing medications, especially with longer duration of use (OR >8 years = 3.00, 95% confidence interval (CI) = 1.4-6.5). In contrast, use of paracetamol did not relate overall to risk of bladder cancer. We also found that regular use of any NSAID was associated with a statistically significant decrease in bladder cancer risk (OR = 0.6, 95% CI = 0.4-0.9), and specifically use of aspirin. Further, the association with NSAID use was largely among invasive, high grade and TP53 positive tumors. CONCLUSION: While these agents have been investigated in several studies, a number of questions remain regarding the effects of analgesic and NSAID use on risk of bladder cancer.
PubMed ID:
17692123
MeSH Terms: Aged; Analgesics/therapeutic use*; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use; Aspirin/therapeutic use; Case-Control Studies; Female; Humans; Male; Middle Aged; Population Surveillance*/methods; Risk Factors; Urinary Bladder Neoplasms/epidemiology*; Urinary Bladder Neoplasms/prevention & control*